Skip to content

Press Release · Press Releases

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Issued by PR Newswire

Image: PR Newswire

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levels First-line treatment options...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

APOD: 2026 October 25 – Dark Matter in a Simulated Universe

APOD Science APOD APOD: 2026 October 25 – Dark… Today’s APOD Archive Submissions Index Search Calendar RSS Education About Discuss APOD Astronomy Picture of the Day Discover the cosmos! Each day a different image or photograph of our fascinating universe is featured, along with a brief explanation written by a professional astronomer. Dark Matter […]

NASA ·